The serum angiotensin-converting enzyme 2 and angiotensin-(1-7) concentrations after optimal therapy for acute decompensated heart failure with reduced ejection fraction.


Journal

Bioscience reports
ISSN: 1573-4935
Titre abrégé: Biosci Rep
Pays: England
ID NLM: 8102797

Informations de publication

Date de publication:
26 06 2020
Historique:
received: 03 08 2019
revised: 26 05 2020
accepted: 26 05 2020
pubmed: 28 5 2020
medline: 25 3 2021
entrez: 28 5 2020
Statut: ppublish

Résumé

Elucidation of the role of angiotensin-converting enzyme (ACE) 2 (ACE2)/angiotensin (Ang)-(1-7)/Mas receptor axis in heart failure is necessary. No previous study has reported serial changes in ACE2 and Ang-(1-7) concentrations after optimal therapy (OT) in acute heart failure (AHF) patients. We aimed to investigate serial changes in serum ACE2 and Ang-(1-7) concentrations after OT in AHF patients with reduced ejection fraction (EF). ACE2 and Ang-(1-7) concentrations were measured in 68 AHF patients with reduced EF immediately after admission and 1 and 3 months after OT. These parameters were compared with the healthy individuals at three time points. In the acute phase, Ang-(1-7) and ACE2 concentrations was statistically significantly lower and higher in AHF patients than the healthy individuals (2.40 ± 1.11 vs. 3.1 ± 1.1 ng/ml, P<0.005 and 7.45 ± 3.13 vs. 4.84 ± 2.25 ng/ml, P<0.005), respectively. At 1 month after OT, Ang-(1-7) concentration remained lower in AHF patients than the healthy individuals (2.37 ± 1.63 vs. 3.1 ± 1.1 ng/ml, P<0.05); however, there was no statistically significant difference in ACE2 concentration between AHF patients and the healthy individuals. At 3 months after OT, there were no statistically significant differences in Ang-(1-7) and ACE2 concentrations between AHF patients and the healthy individuals. ACE2 concentration was equivalent between AHF patients and the healthy individuals at 1 and 3 months after OT, and Ang-(1-7) concentration was equivalent at 3 months after OT.

Identifiants

pubmed: 32458985
pii: 225014
doi: 10.1042/BSR20192701
pmc: PMC7295637
pii:
doi:

Substances chimiques

Biomarkers 0
Peptide Fragments 0
Angiotensin I 9041-90-1
ACE2 protein, human EC 3.4.17.23
Angiotensin-Converting Enzyme 2 EC 3.4.17.23
angiotensin I (1-7) IJ3FUK8MOF

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2020 The Author(s).

Références

Hypertension. 2001 Jul;38(1):90-4
pubmed: 11463766
Circ J. 2013;77(8):2157-201
pubmed: 23759659
Horm Metab Res. 1998 Aug;30(8):490-5
pubmed: 9761377
N Engl J Med. 2020 May 1;:
pubmed: 32356626
J Endocrinol. 1981 Dec;91(3):457-65
pubmed: 7035596
Science. 2020 Mar 27;367(6485):1444-1448
pubmed: 32132184
Circulation. 1996 Aug 15;94(4):690-7
pubmed: 8772689
J Hypertens. 2001 Mar;19(3 Pt 2):635-9
pubmed: 11327640
Nat Rev Cardiol. 2020 May;17(5):259-260
pubmed: 32139904
Circulation. 2003 Feb 18;107(6):807-10
pubmed: 12591748
Heart Vessels. 2017 Mar;32(3):303-308
pubmed: 27421979
Proc Natl Acad Sci U S A. 1988 Jun;85(11):4095-8
pubmed: 3375255
Hypertens Res. 2011 Feb;34(2):154-60
pubmed: 21124322
Clin Sci (Lond). 2012 Aug 1;123(4):193-203
pubmed: 22548405
Circulation. 2007 Apr 3;115(13):1754-61
pubmed: 17372171
N Engl J Med. 1991 Aug 1;325(5):293-302
pubmed: 2057034
N Engl J Med. 1987 Jun 4;316(23):1429-35
pubmed: 2883575
Cardiovasc Drugs Ther. 1995 Feb;9(1):145-9
pubmed: 7786835
Cardiovasc Drugs Ther. 2018 Apr;32(2):213-222
pubmed: 29679303
Nature. 2002 Jun 20;417(6891):822-8
pubmed: 12075344
Eur J Heart Fail. 2014 Jul;16(7):817-25
pubmed: 24828035
J Biol Chem. 2002 Apr 26;277(17):14838-43
pubmed: 11815627
Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8258-63
pubmed: 12829792
J Am Coll Cardiol. 2019 Apr 23;73(15):1931-1944
pubmed: 30999996
J Pathol. 2004 Jun;203(2):631-7
pubmed: 15141377
Circulation. 2001 Jan 2;103(1):72-7
pubmed: 11136688
Hypertension. 2010 Feb;55(2):207-13
pubmed: 20038757
Circulation. 2003 Sep 16;108(11):1306-9
pubmed: 12939207
Hypertension. 2006 Apr;47(4):718-26
pubmed: 16505206
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Exp Physiol. 2008 May;93(5):519-27
pubmed: 18310257
Circulation. 2003 Oct 7;108(14):1707-12
pubmed: 14504186
N Engl J Med. 1971 Dec 23;285(26):1441-6
pubmed: 5122894
N Engl J Med. 2020 Apr 23;382(17):1653-1659
pubmed: 32227760
J Am Coll Cardiol. 2008 Aug 26;52(9):755-7
pubmed: 18718424

Auteurs

Shinji Hisatake (S)

Department of Cardiovascular Medicine, Toho University Graduate School of Medicine, Tokyo, Japan.

Shunsuke Kiuchi (S)

Department of Cardiovascular Medicine, Toho University Graduate School of Medicine, Tokyo, Japan.

Takayuki Kabuki (T)

Department of Cardiovascular Medicine, Toho University Graduate School of Medicine, Tokyo, Japan.

Takashi Oka (T)

Department of Cardiovascular Medicine, Toho University Graduate School of Medicine, Tokyo, Japan.

Shintaro Dobashi (S)

Department of Cardiovascular Medicine, Toho University Graduate School of Medicine, Tokyo, Japan.

Takahiro Fujii (T)

Department of Cardiovascular Medicine, Toho University Graduate School of Medicine, Tokyo, Japan.

Takanori Ikeda (T)

Department of Cardiovascular Medicine, Toho University Graduate School of Medicine, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH